Phase 2 Trial of Docetaxel, Gemcitabine, and Oxaliplatin Combination Chemotherapy in Platinum- and Paclitaxel-Pretreated Epithelial Ovarian Cancer. Issue 8 (1st November 2009)

• Record Type: Journal Article
• Authors: Seliger, Gregor; Mueller, Lutz P.; Kegel, Thomas; Kantelhardt, Eva J.; Grothey, Axel; GroßE, Regina; Strauss, Hans-Georg; Koelbl, Heinz; Thomssen, Christoph; Schmoll, Hans-Joachim
• Is Part Of: International journal of gynecological cancer. Volume 19:Issue 8(2009)
• Page Start: 1446-1453
• Page End: 1446-1453
• Publication Date: 2009-11-01
• Subjects: Docetaxel -- Gemcitabine -- Oxaliplatin -- Ovarian cancer -- Platinum-refractory; Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1111/IGC.0b013e3181b62f38
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Background: This phase 2 trial was designed to evaluate the efficacy and toxicity of a combination of docetaxel, gemcitabine, and oxaliplatin for platinum- and paclitaxel-pretreated epithelial ovarian cancer. Patients and Methods: Heavily pretreated patients (N = 30; median age, 61 years) received docetaxel, 55 mg/m 2 ; gemcitabine, 500 mg/m 2 (day 1); and oxaliplatin, 70 mg/m 2 (day 2) biweekly. Twelve patients had platinum-sensitive disease, and 18 patients had platinum-resistant disease. Results: Median follow-up was 18.6 months. No differences in patient characteristics were observed between patients with carboplatinum-sensitive and carboplatinum-resistant disease. In patients with carboplatin-sensitive disease, an overall response (OR) of 83.3%, a progression-free survival of 10.6 months, and an overall survival of 18.9 months were observed. In patients with carboplatinum-resistant disease, an OR was seen in 38.9% with a progression-free survival of 5.3 months and an overall survival of 16.3 months. Patients with platinum-refractory disease (progression under previous carboplatinum therapy, n = 13) had an OR of 23%, whereas patients with objective response but relapse less than 6 months after carboplatinum therapy had an OR of 80.0%. Grade 3 and 4 toxicities were only observed for anemia (6.7%), neutropenia (20.0%), thrombopenia, peripheral neuropathy, and diarrhea (16.7%). No neutropenic fever or treatment-related death occurred. Conclusions: In comparison with current standard protocols, a combination of docetaxel, gemcitabine, and oxaliplatin showed considerably higher efficacy without remarkable increased toxicity; particularly for patients with early relapse after a platinum-containing therapy.